All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your ALL Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
ZUMA-3 trial update of brexucabtagene autoleucel in adult patients with R/R B-ALL
Featured
Bookmark this article
During the 2022 ASCO Annual Meeting, the ALL Hub spoke with Bijal D. Shah, Moffit Cancer Center, Tampa, US. We asked for a ZUMA-3 trial update of brexucabtagene autoleucel in adult patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL).
ZUMA-3 trial update of brexucabtagene autoleucel in adult patients with R/R B-ALL
Shah shares data from the 2-year follow-up of the ZUMA-3 trial, discussing the long-term impact of allogeneic stem cell transplants. Shah outlines promising findings on overall survival for different patient groups and highlights a lack of trend in toxicity data.
Your opinion matters
6 votes - 49 days left ...
Related articles
Newsletter
Subscribe to get the best content related to ALL delivered to your inbox